December 5th, 2024 | 07:15 CET
Evotec has exploded – Will BioNxt Solutions and Bayer follow suit?
The biotechnology and pharmaceutical industries are among the most advanced and forward-looking sectors of the global economy. With the development of innovative drugs, therapies, and technologies, the industry is pursuing the goal of sustainably improving the quality of life of millions of people. Intensive research, enormous investments, and a strong focus on groundbreaking innovations define this field, where science and technology work together in close cooperation. Companies such as Evotec, Bayer, and BioNxt Solutions are among the most interesting players in Germany. We take a look at the latest developments.
time to read: 4 minutes
|
Author:
Armin Schulz
ISIN:
EVOTEC SE INH O.N. | DE0005664809 , Bionxt Solutions Inc. | CA0909741062 , BAYER AG NA O.N. | DE000BAY0017
Table of contents:
Author
Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
Tag cloud
Shares cloud
Evotec – What is next after the takeover withdrawal?
Evotec's share price exploded on the back of the takeover rumors and Halozyme's now-withdrawn takeover bid. But what happens now? The figures for the first nine months show a slight decline in sales of 1% to EUR 575.7 million due to challenging market conditions. Despite these challenges, the Company has achieved significant progress, particularly through collaborations with leading companies such as Bristol Myers Squibb, Novo Nordisk, and Pfizer. These partnerships aim to develop innovative treatments and strengthen Evotec's position in research and development. Particularly noteworthy is the strong growth of Just - Evotec Biologics, which has become a key revenue driver thanks to its collaboration with Sandoz.
Despite challenging market conditions, Evotec continues to push ahead with its transformation plans. The "Priority Reset" initiative is expected to contribute to an annual increase in adjusted EBITDA of over EUR 40 million from the second half of 2024. At the same time, measures to improve liquidity were implemented, with actual one-time costs below initial expectations. The expansion of production capabilities, notably with the opening of a state-of-the-art biologics facility in Toulouse, underpins Evotec's strategic direction in the biologics sector.
By the end of the year, Chief Operating Officer Dr. Craig Johnstone, who has been in office since 2019, will be leaving the Company. During his time with Evotec, he played a key role in optimizing global operations. His responsibilities will be temporarily distributed internally until a new organizational structure is introduced. This change coincides with a strategic realignment aimed at increasing long-term efficiency and productivity. If the coming year turns out to be calmer and research results, particularly in strategic partnerships, are positive, the stock should have further potential. It is currently consolidating and trading at EUR 8.645.
BioNxt Solutions - Developing a new delivery method for Semaglutide
The Canadian biotechnology company BioNxt Solutions plans to revolutionize the way Semaglutide, a leading drug for type 2 diabetes and obesity from Novo Nordisk, is administered. Currently, the drug is mainly administered by injection, which deters some patients and limits adherence to treatment. BioNxt is addressing this issue using sublingual film-melt technology. This innovative method aims to simplify administration and enhance patient comfort – an essential advantage in consistently growing markets. In 2023, Semaglutide generated over USD 14 billion in revenue, highlighting the significant market potential for an improved delivery system.
BioNxt's innovative, orodispersible film could set new standards. Unlike injections or tablets, the film allows for easy placement under the tongue, where the active ingredient is absorbed directly through the oral mucosa. This effectively increases bioavailability while minimizing enzymatic degradation. In addition, the method takes effect quickly and offers an attractive alternative to patients with a fear of needles. This development reflects the trend towards patient-centered solutions and could open up additional revenue potential for Novo Nordisk – especially in a market with over 537 million diabetes patients worldwide.
A possible cooperation with Novo Nordisk could generate long-term revenues for BioNxt, while the Danish pharmaceutical giant could further expand its leading market position – a win-win situation with great potential. The Company has a strong innovation pipeline, which ranges from the treatment of neurodegenerative autoimmune diseases to anti-aging products, and is protected by more than 40 international patents. Most recently, national patent applications for sublingual cancer drugs to treat neurodegenerative autoimmune diseases were filed on October 29. For several days, the stock has been trading below the daily candles, indicating potential buying interest. The value is currently trading at CAD 0.22.
Bayer – Struggling with financial setbacks but counting on innovation
The pharmaceutical and agrochemical company Bayer finds itself in a challenging financial position, as highlighted by its Q3 figures. Revenue fell by 3.6% to just under EUR 10 billion, while the Company recorded a net loss of EUR 4.18 billion. Despite a slight improvement compared to the previous year, key metrics fell short of analyst expectations. Looking ahead at the full year, Bayer expects underlying operating profit to decline to between EUR 10.4 billion and EUR 10.7 billion – underlining the ongoing challenges, particularly in its agricultural division.
To overcome the difficult situation, Bayer is focusing on targeted partnerships and new business areas. One example of this is the collaboration with the start-up Impli. Together, the companies are working on innovative solutions for hormone diagnostics with the aim of improving access to modern fertility treatments. This partnership is part of Bayer's overarching strategy of tapping into new growth markets and thus counteracting economic pressure.
In addition, the Leverkusen-based company is relying on a combination of innovation and sustainable action to remain competitive in the long term. The Company is investing more in the development of environmentally friendly agricultural products and digital health solutions. The aim is to take on ecological and social responsibility in addition to economic stability. With this commitment, Bayer not only aims to secure its market position but also increase the Company's value in the long term. The share is currently available for EUR 19.20.
The biotechnology and pharmaceutical industry is showing both innovative strengths and challenges. Evotec is driving its transformation through strategic partnerships with companies such as Pfizer and Novo Nordisk and focusing on profitable growth. BioNxt Solutions is developing an exciting semaglutide delivery method using a sublingual orodispersible film technology that offers new market potential for both Novo Nordisk and BioNxt. Bayer, on the other hand, is struggling with financial hurdles but is focusing on innovations in agriculture and healthcare solutions to promote stability and sustainability.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
